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SAT0413   DACTYLITIS IS ASSOCIATED WITH DISEASE SEVERITY AND ULTRASOUND DEFINED 
EROSIVE DAMAGE IN VERY EARLY, DMARD NAÏVE PSORIATIC ARTHRITIS FREE 
S. Dubash1, O. Alabas1, X. Michelena1, G. De Marco1, L. Garcia-Montoya1, R. Wakefield1, A. L. Tan1, 
P. Helliwell1, P. Emery1, D. Mcgonagle1, H. Marzo-Ortega1 
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Abstract 
Background: Dactylitis is a hallmark feature of Psoriatic arthritis (PsA) and Spondyloarthritis (SpA) 
ĚĞĨŝŶĞĚĂƐĂƵŶŝĨŽƌŵƐǁĞůůŝŶŐŽĨĂĚŝŐŝƚ ? ?ƐĂƵƐĂŐĞĚŝŐŝƚ ? ? ?ĂĐƚǇůŝƚŝƐŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƌĂĚŝŽŐƌĂƉŚŝĐ
damage in chronic PsA. However, there are a paucity of data on the significance of dactylitis and its 
potential impact in disease burden in early PsA. 
Objectives: To characterize a very early DMARD naïve PsA cohort based on clinical presence or 
absence of dactylitis at disease onset. 
Methods: PsA subjects fulfilling the CASPAR classification criteria, were recruited into a prospective 
observational cohort, the Leeds Spondyloarthropathy Register for Research and Observation 
(SpARRO) after providing informed written consent. Clinical data including tender (TJC) and swollen 
joint counts (SJC) were independently assessed. Dactylitis was recorded per digit (finger or toe) as 
tender (hot) or non-tender (cold). Differences in baseline characteristics were evaluated using 
percentages to describe categorical variables and means and standard deviations for continuous 
variables, p value of the mean/proportion difference was calculated. Ultrasound (US) examination 
was conducted by trained ultra-sonographers blinded to clinical details. Bone erosions were defined 
on US if intra-articular discontinuity was present in two perpendicular planes at any of 46 joints: 
wrists, MCP1-5, PIP2-5, DIP2-5, MTP1-5, knees, ankles, subtalar, talonavicular. 
Results: A total of 177 PsA patients were recruited. Dactylitis was seen in nearly half the cohort 
[n=83 (47%)]. Patients with dactylitis had significantly more early morning stiffness, higher TJC and 
SJC, compared with non-dactylitis (Table 1). A total of 211 digits with dactylitis were recorded in 83 
patients. Dactylitis of multiple digits was seen in 47/83 (57%) patients whilst a single dactylitic digit 
occurred in 36/83 (43%). Foot involvement was more prevalent (141/211, 67%) than hands (70/211, 
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tender dactylitis (58/211, 27.5%). The most prevalent sites for hot dactylitis were toes 2-4th and 
fingers 2-3rd. 
US defined erosions were significantly more prevalent in the dactylitis group: 34 erosions in 21/71 
patients (29.5%) versus 16 erosions in 12/83 (14.4%) patients in non-dactylitis. Sites prone to erosive 
damage in both groups were the wrists, MCP1,2 and MTP4,5. The right MCP2 (n=6) and MTP5 (n=6) 
were most commonly eroded in the dactylitis group, but erosions corresponding at the dactylitic 
digit level were overall low. 
Conclusion: This study identifies a more severe phenotype in very early DMARD naïve PsA 
presenting with dactylitis with higher prevalence of ultrasound erosions. Longitudinal follow up will 
determine whether dactylitis represents a poor prognostic factor in very early PsA, which may be a 
useful discriminator for risk stratification in future PsA management recommendations. 
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Table 1. 
Variable No Dactylitis (n=94) Dactylitis (n=83) P value 
Age, mean (SD) years 44.4 (12.8) 43.7 (13.2) >0.05 
Male 38 (40.4%) 42 (50.6%) >0.05 
Disease duration, median (IQR) weeks 4.7 (0.0-11.4) 5.2 (1-22.4) >0.05 
Early Morning stiffness, mean (SD) mins 82.8 (145.4) 170.5 (230.2) 0.0025* 
TJC (78), mean (SD) 8.3 (10.9) 13.7 (14.0) 0.004* 
SJC (76), mean (SD) 2.2 (3.2) 8.4 (8.0) <0.001* 
Psoriasis 94/94 (100.0%) 76/83 (91.6%) 0.004* 
PASI, mean (SD) 3.6 (4.0) 3.0 (4.1) >0.05 
Nail Dystrophy 51/94 (54.3%) 41/83 (49.4%) >0.05 
mNAPSI, mean (SD) 4.9 (7.1) 7.5 (14.0) >0.05 
MASES, mean (SD) 1.6 (2.9) 1.5 (2.4) >0.05 
BMI, mean (SD) 29.1 (6.4) 28.6 (5.6) >0.05 
Smoker 19.0 (20.2%) 9.0 (10.8%) >0.05 
ůĞǀĂƚĞĚZW ?х ? ?രŵŐ ?> ? 24 (25.5%) 36 (43.4%) >0.05 
PsAQoL, mean (SD) 6.2 (6.6) 6.2 (6.1) >0.05 
HAQ, mean (SD) 0.79 (0.71) 0.84 (0.65) >0.05 
US Erosions (n=154) 12/83 (14.4%) 21/71 (29.5%) 0.023* 
 
